Valproate and Women of Childbearing Potential: Sanofi Discusses the Updated Recommendations

This is a promotional 30-minute webinar by Sanofi to address key topics at the forefront of epilepsy management. Prescribing information can be found here. Adverse events reporting information can be found at the end of this email.

Dear %customer.firstname% %customer.lastname%,

We would like to invite you to register for the first Coffee Club to be held on 26 June 2019 entitled:

Valproate and Women of Childbearing Potential:
Sanofi Discusses the
Updated Recommendations

REGISTRATION NOW OPEN

Do you prescribe valproate to your female patients with epilepsy? Learn about the restrictions on the use of valproate in women of childbearing potential.

Join us to hear how you can help your patient switch to another antiepileptic medication; or, if no other antiepileptic drug is suitable, what you and your patient need to do to comply with the pregnancy prevention programme.

We hope to see you there!

Kind regards,

%employee_name%

Your local valproate representative
On behalf of Sanofi

In this coffee club we will cover the following:

Latest requirements on the use of valproate in women of childbeairng potential
How to access the Valproate Risk Minimisation Educational Materials that provide you with an HCP guide, patient guide to give to your patient, and an annual risk acknowledgment form to be completed with your patient
- the valproate pregnancy prevention programme that you and your patient need to follow if no other antiepileptic drug is effective
Evidence for the teratogenic effects of valproate
Practical guidance on how best to switch your patient to another antiepileptic medication

We hope you will join us for this very important discussion

Yours sincerely,

ERIC TEO

Qualified Person for Pharmacovigilance, Sanofi

LUCIA ARGANDONA

Neurologist, Senior Medical Advisor, Sanofi

The webinar will provide clarity on the recommendatons around the use of valproate to help you support your female patients

We hope you will be able to join us.

SAGB.VPA.18.06.0873r
Date of prep: June 2019

You have received this email because you have previously agreed for Sanofi (including Aventis Pharma Limited, Genzyme Therapeutics Limited and/or Sanofi-Aventis Ireland Limited) to contact you by email with information which we feel may be of interest to you.

If you do not wish to continue receiving these communications by email, please contact us via email gfd-webmaster@sanofi.com with the word ‘Unsubscribe’ in the subject line.

For any other questions, please contact us at
uk-medicalinformation@Sanofi.com
or Sanofi, One Onslow Street, Guildford, Surrey, GU1 4YS, UK.

▼ This medicinal product is subject to additional monitoring. This will allow quick identifiation of new safety information. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard

Adverse events should also be reported to Sanofi Tel: 0800 0902314. Alternatively, send via E-mail to UK-drugsafety@sanofi.com